

H. Mbarek, H. Ochi, Y. Urabe, V. Kumar, M.Kubo, N. Hosono, A. Takahashi, Y. Kamatani, D. Miki, H. Abe, T. Tsunoda, N. Kamatani, K. Chayama, Y. Nakamura, K. Matsuda	A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population.	Human molecular genetics.	20(19)	3884-3892	2011
J. Li, D. Yang, Y. He, M. Wang, Z. Wen, L. Liu, J. Yao, K. Matsuda, Y. Nakamura, J. Yu, X. Jiang, S. Sun, Q. Liu, Q. Song, M. Chen, H. Yang, F. Tang, X. Hu, J. Wang, Y. Chang, X. He, Y. Chen, J. Lin	Associations of HLA-DP variants with hepatitis B virus infection in southern and northern Han Chinese populations: a multicenter case-control study.	PloS one	6(8)	e24221	2011
V.Kumar, N.Kato, Y.Urabe, A.akahashi, R.Muroyama, N.Hosono, .Otsuka, R.Tateishi, M.Omata, H.Nakagawa, K.Koike, N.Kamatani, M.Kubo, Y.Nakamura, K.Matsuda,	Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma.	Nature genetics	43(5)	455-458	2011
J.C. Chambers, K. Matsuda, et al.	Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma.	Nature genetics	43	1131-1138.	2011
Y.J. Kim, M.J. Go, C. Hu, C.B. Hong, Y.K. Kim, J.Y. Lee, J.Y. Hwang, J.H. Oh, D.J. Kim, N.H. Kim, S. Kim, E.J. Hong, J.H. Kim, H. Min, Y. Kim, R. Zhang, W. Jia, Y. Okada, A. Takahashi, M. Kubo, T. Tanaka, N. Kamatani, K. Matsuda, T. Park, B. Oh, K. Kimm, D. Kang, C. Shin, N.H. Cho, H.L. Kim, B.G. Han, Y.S. Cho,	Large-scale genome-wide association studies in east Asians identify new genetic loci influencing metabolic traits.	Nature genetics	43	990-995	2011

Yoshimi A, Yamamoto G, Goto T, Koike K, Kurokawa M	Hepatocellular carcinoma in cirrhotic liver with graft-versus-host disease	Ann Hematol		2012 Feb 9.[Epub ahead of print]	
Goto E, Masuzaki R, Tateishi R, Kondo Y, Imamura J, Goto T, Ikeda H, Akahane M, Shiina S, Omata M, Yoshida H, Koike K	Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma	J Gastroenterol		2011 Dec 27. [Epub ahead of print]	
Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K	Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors	Am J Gastroenterol		2011 Dec 13. doi: 10.1038/ajg.2011.425. [Epub ahead of print]	
Ohki T, Tateishi R, Akahane M, Shiina S, Yamashiki N, Mikami S, Enooku K, Goto E, Masuzaki R, Kondo Y, Goto T, Inoo S, Ohtomo K, Omata M, Yoshida H, Koike K	Characteristics of hepatocellular carcinoma nodules newly detected by computed tomography during arteriography and arterial portography: preliminary report of a randomized controlled trial	Hepatol Int		2011 Aug 31. [Epub ahead of print]	
Enooku K, Tateishi R, Kanai F, Kondo Y, Masuzaki R, Goto T, Shiina S, Yoshida H, Omata M, Koike K	Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times	J Gastroenterol		2011 Sep 21. [Epub ahead of print]	
Takata A, Otsuka M, Kogiso T, Kojima K, Yoshikawa T, Tateishi R, Kato N, Shiina S, Yoshida H, Omata M, Koike K	Direct differentiation of hepatic cells from human induced pluripotent stem cells using a limited number of cytokines.	Hepatol Int		2011 Feb 6. [Epub ahead of print]	

Inoue H, Yamazaki S, Shimizu M, Uozaki H, Goto T, Ohnishi S, Koike K	Liver injury induced by the Japanese herbal drug kamishoyosan	Gastroenterol Hepatol (NY)	7(10)	692-695	2011
Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, Goto E, Masuzaki R, Asaoka Y, Kondo Y, Goto T, Shiina S, Omata M, Yoshida H, Koike K	Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients	Int J Cancer	129	2226-2235	2011
Goto T, Yoshida H, Tateishi R, Enooku K, Goto E, Sato T, Ohki T, Masuzaki R, Imamura J, Shiina S, Koike K, Omata M	Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation	Hepatol Int	5(3)	767-773	2011
Taguwa S, Kambara H, Fujita N, Noda T, Yoshimori T, Koike K, Moriishi K, Matsuura Y	Dysfunction of autophagy participates in vacuole formation and cell death in cells replicating hepatitis C virus	J Virol	85	13185-13194	2011
Kudo Y, Tanaka Y, Tateishi K, Yamamoto K, Yamamoto S, Mohri D,	Altered composition of fatty acids exacerbates hepatotumorigenesis	J Hepatol	55(6)	1400-1408	2011
Isomura Y, Seto M, Nakagawa H, Asaoka Y, Tada M, Ohta M, Ijichi H, Hirata Y, Otsuka M, Ikenoue T, Maeda S, Shiina S, Yoshida H, Nakajima O, Kanai F, Omata M, Koike K	during activation of the phosphatidylinositol 3-kinase pathway				

Ishizaka N, Hongo M, Sakamoto A, Saito K, Furuta K, Koike K	Liver lipid content is reduced in rat given 7-day administration of angiotensin II	J Renin Angiotensin Aldosterone Syst	12(4)	462-468	2011
Bertot LC, Sato M, Tateishi R, Yoshida H, Koike K	Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review	Eur Radiol	21(12)	462-468	2011
Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Yoshida H, Aoki T, Hasegawa K, Akahane M, Ohtomo K, Fukayama M, Koike K, Kokudo N	Diagnostic accuracy of α -fetoprotein and des- γ -carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates	Hepatol Res	41(12)	1199-1207	2011
Fujinaga H, Tsutsumi T, Yotsuyanagi H, Moriya K, Koike K	Hepatocarcinogenesis in hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species	Oncology	Suppl 1	11-17	2011
Ikeda H, Tateishi R, Enooku K, Yoshida H, Nakagawa H, Masuzaki R, Kondo Y, Goto T, Shiina S, Kume Y, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Ono T, Koike K, Yatomi Y	Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C	Cancer Epidemiol Biomarkers Prev	20(10)	2204-2211	2011
Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M ; PERFECT Study Group.	Cancer preventive effect of pegylated interferon α -2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis.	Hepatol Res	41(10)	955-964	2011

Otsuka M, Takata A, Yoshikawa T, Kojima K, Kishikawa T, Shibata C, Takekawa M, Yoshida H, Omata M, Koike K	Receptor for Activated Protein Kinase C: Requirement for Efficient MicroRNA Function and Reduced Expression in Hepatocellular Carcinoma. PLoS One	PLoS One	6(9)	e24359.	2011
Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, Goto T, Omata M, Yoshida H, Koike K	Hepatocellular carcinoma with extrahepatic metastasis: Clinical features and prognostic factors.	Cancer	117(19)	4475-4483	2011
Takata A, Otsuka M, Kojima K, Yoshikawa T, Kishikawa T, Yoshida H, Koike K	MicroRNA-22 and microRNA-140 suppress NF- κ B activity by regulating the expression of NF- κ B coactivators	Biochem Biophys Res Commun	411(4)	826-831	2011
Wakita T, Suzuki T, Evans MJ, Shimotohno K, Chayama K, Matsuura Y, Hijikata M, Moriishi K, Seya T, Enomoto N, Koike K, Kato N, Kanto T, Hotta H	Will There Be an HCV Meeting in 2020? Summary of the 17th International Meeting on Hepatitis C Virus and Related Viruses.	Gastroenterology	141(1)	e1-5	2011
Nakagawa H, Hirata Y, Takeda K, Hayakawa Y, Sato T, Kinoshita H, Sakamoto K, Nakata W, Hikiba Y, Omata M, Yoshida H, Koike K, Ichijo H, Maeda S	Apoptosis signal-regulating kinase 1 inhibits hepatocarcinogenesis by controlling the tumor-suppressing function of stress-activated MAPK	Hepatology	54(1)	185-195	2011
Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, Kondo Y, Kang YJ, Kishikawa T, Kato N, Xie Z, Zhang WJ, Yoshida H, Omata M, Nepveu A, Koike K	MicroRNA122 is a key regulator of α -fetoprotein expression and biologically aggressive behavior of hepatocellular carcinoma	Nat Commun	2	338	2011

Tsukada K, Sugawara Y, Kaneko J, Tamura S, Tachikawa N, Morisawa Y, Okugawa S, Kikuchi Y, Oka S, Kimura S, Yatomi Y, Makuuchi M, Kokudo N, Koike K	Living donor liver transplantations in HIV- and hepatitis C virus-coinfected hemophiliacs: Experience in a Single Center	Transplantation	91(11)	1261-1264	2011
Koshiyama A, Ichibangase T, Moriya K, Koike K, Yazawa I, Imai K	Liquid chromatographic separation of proteins derivatized with a fluorogenic reagent at cysteinyl residues on a non-porous column for differential proteomics analysis	J Chromatogr A	1218(2)	3447-3452	2011
Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, Otuska M, Tateishi R, Omata M, Nakagawa H, Koike K, Kamatani N, Kubo M, Nakamura Y, Matsuda K	Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma	Nat Genet	43(5)	455-458	2011
Nakagawa H, Ikeda H, Nakamura K, Ohkawa R, Masuzaki R, Tateishi R, Yoshida H, Watanabe N, Tejima K, Kume Y, Iwai T, Suzuki A, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Omata M, Igarashi K, Aoki J, Koike K, Yatomi Y	Autotaxin as a novel serum marker of liver fibrosis	Clin Chim Acta	412(13-14)	1201-1206	2011
Kershenobich K, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K, Han K-H, Wallace CM, Zeuzem S, Negro F	The global health burden of hepatitis C virus infection	Liver Int	31(S2)	4-17	2011

Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, AlOmair A, Amarapurkar D, Chen C-H, Dou X, El Khayat H, elShazly M, Esmat G, Guan R, Han K-H, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F	A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.	Liver Int	31(S2)	61-80	2011
Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; The Japan NASH Study Group, The Ministry of Health, Labour and Welfare of Japan.	Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma	Clin Gastroenterol Hepatol	9(5)	428-433	2011
Koike K, Miyoshi H, Yotsyanagi H, Moriya K.	Effect of treatment with polyunsaturated fatty acids on HCV-or diet-induced fatty liver	J Hepatol	54	1325-1326	2011
Masuzaki R, Shiina S, Tateishi R, Yoshida H, Goto E, Sugioka Y, Kondo Y, Goto T, Ikeda H, Omata M, Koike K	Utility of contrast enhanced ultrasonography with sonazoid in radiofrequency ablation for hepatocellular carcinoma	J Gastroenterol Hepatol	26(4)	759-764	2011
Miyoshi H, Moriya K, Tsutsumi T, Shinzawa S, Fujie H, Shintani Y, Fujinaga H, Goto K, Todoroki T, Suzuki T, Miyamura T, Matsuura Y, Yotsuyanagi H, Koike K.	Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein.	J Hepatol.	54(3)	432-8.	2011

Kondo Y, Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Masuzaki R, Asaoka Y, Fujie H, Goto T, Omata M, Yoshida H, Koike K	Intrahepatic bile duct dilatation after percutaneous radiofrequency ablation for hepatocellular carcinoma: impact on patient's prognosis	Liver Int	31	197-205	2011
Mizokami Masashi	Discovery of critical host factor, IL-28B, associated with response to hepatitis C virus treatment.	J Gastroenterol Hepatol.	27(3)	425-9	2012
Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M.	Genetic variation of the IL-28B promoter affecting gene expression.	PLoS One	6(10)	e26620	2011
Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Matsuura K, Sugauchi F, Enomoto N, Nishida N, Tokunaga K, Mizokami M, Izumi N.	Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.	Antivir Ther	16(5)	685-694	2011
Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, Enomoto N, Yatsuhashi H, Nishiguchi S, Hino K, Hige S, Itoh Y, Tanaka E, Mochida S, Honda M, Hiasa Y, Koike A, Sugauchi F, Kaneko S, Izumi N, Tokunaga K, Mizokami M.	Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.	Hum Mol Genet.	20(17)	3507-3516	2011

Ito K, Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H, Aoki Y, Sato Y, Imamura M, Murata K, Nomura H, Hige S, Adachi H, Hino K, Yatsushashi H, Orito E, Kani S, Tanaka Y, Mizokami M.	The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.	J Clin Microbiol.	49(5)	1853-60	2011
Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M; the Ochanomizu-Liver Conference Study Group.	Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.	J Med Virol.	83(5):	871-878	2011
Sugiyama M, Tanaka Y, Nakanishi M, Mizokami M.	Novel findings for the development of drug therapy for various liver diseases: Genetic variation in IL-28B is associated with response to the therapy for chronic hepatitis C.	J Pharmacol Sci.	115(3)	263-9	2011
Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M; Ochanomizu-Liver Conference Study Group.	Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.	J Med Virol.	83(5)	871-8	2011
Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, Enomoto N, Yatsushashi H, Nishiguchi S, Hino K, Hige S, Itoh Y, Tanaka E, Mochida S, Honda M, Hiasa Y, Koike A, Sugauchi F, Kaneko S, Izumi N, Tokunaga K, Mizokami M.	Genome-wide association study identified ITPA/DDR1GK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.	Hum Mol Genet.	20(17)	3507-16	2011

<p>Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Matsuura K, Sugauchi F, Enomoto N, Nishida N, Tokunaga K, Mizokami M, Izumi N</p>	<p>Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.</p>	<p>Antivir Ther</p>	<p>16(5)</p>	<p>685-94</p>	<p>2011</p>
<p>Ogoshi K, Hashimoto SI, Nakatani Y, Qu W, Oshima K, Tokunaga K, Sugano S, Hattori M, Morishita S, Matsushima K</p>	<p>Genome-wide profiling of DNA methylation in human cancer cells.</p>	<p>Genomics</p>	<p>98(4)</p>	<p>280-287</p>	<p>2011</p>
<p>Nishida N, Mawatari Y, Sageshima M, Tokunaga K.</p>	<p>Highly Parallel and Short-Acting Amplification with Locus-Specific Primers to Detect Single Nucleotide Polymorphisms by the DigiTag2 Assay.</p>	<p>PLoS One.</p>	<p>7(1)</p>	<p>e29967</p>	<p>2012</p>

Ⅲ. 研究成果の刊行物、別刷

A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region

Yuji Urabe^{1,2}, Hidenori Ochi², Naoya Kato⁴, Vinod Kumar^{1,3}, Atsushi Takahashi³, Ryosuke Muroyama⁴, Naoya Hosono³, Motoyuki Otsuka⁵, Ryosuke Tateishi⁵, Paulisally Hau Yi Lo¹, Chizu Tanikawa¹, Masao Omata⁵, Kazuhiko Koike⁵, Daiki Miki², Hiromi Abe², Naoyuki Kamatani³, Joji Toyota⁶, Hiromitsu Kumada⁷, Michiaki Kubo³, Kazuaki Chayama², Yusuke Nakamura^{1,3}, Koichi Matsuda^{1,*}

¹Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; ²Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan; ³Center for Genomic Medicine, The Institute of Physical and Chemical Research (RIKEN), Kanagawa, Japan; ⁴Unit of Disease Control Genome Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; ⁵Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; ⁶Department of Gastroenterology, Sapporo Kosei General Hospital, Hokkaido, Japan; ⁷Department of Hepatology, Toranomon Hospital, Tokyo, Japan

Background & Aims: We performed a genome-wide association study (GWAS) of hepatitis C virus (HCV)-induced liver cirrhosis (LC) to identify predictive biomarkers for the risk of LC in patients with chronic hepatitis C (CHC).

Methods: A total of 682 HCV-induced LC cases and 1045 CHC patients of Japanese origin were genotyped by Illumina Human Hap 610-Quad bead Chip.

Results: Eight SNPs which showed possible associations ($p < 1.0 \times 10^{-5}$) at the GWAS stage were further genotyped using 936 LC cases and 3809 CHC patients. We found that two SNPs within the major histocompatibility complex (MHC) region on chromosome 6p21, rs910049 and rs3135363, were significantly associated with the progression from CHC to LC ($p_{\text{combined}} = 9.15 \times 10^{-11}$ and 1.45×10^{-10} , odds ratio (OR) = 1.46 and 1.37, respectively). We also found that *HLA-DQA1*0601* and *HLA-DRB1*0405* were associated with the progression from CHC to LC ($p = 4.53 \times 10^{-4}$ and 1.54×10^{-4} with OR = 2.80 and 1.45, respectively). Multiple logistic regression analysis revealed that rs3135363, rs910049, and *HLA-DQA1*0601* were independently associated with the risk of HCV-induced LC. In addition, individ-

uals with four or more risk alleles for these three loci have a 2.83-fold higher risk for LC than those with no risk allele, indicating the cumulative effects of these variations.

Conclusions: Our findings elucidated the crucial roles of multiple genetic variations within the MHC region as prognostic/predictive biomarkers for CHC patients.

© 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

Two million people in Japan and 210 million people worldwide are estimated to be infected with the hepatitis C virus (HCV), which is known to be a major cause of chronic viral liver disease [1]. Patients with chronic hepatitis C (CHC) usually exhibit mild inflammatory symptoms, but are at a significantly high risk for developing liver cirrhosis (LC) and hepatocellular carcinoma [2]. More than 400,000 people at present suffer from LC, which is ranked as the 9th major cause of death in Japan. In addition, liver cancer causes approximately 32,000 deaths per year, making it the 4th most common cause of death from malignant diseases. Thus, HCV-related diseases are important public health problems [3].

Clinical outcomes after the exposure to HCV vary enormously among individuals. Approximately 70% of infected persons will develop chronic hepatitis [4], and about 20–30% of CHC patients will develop cirrhosis, but others can remain asymptomatic for decades [2]. The annual death rate of patients with decompensated cirrhosis is as high as 15–30% [5]. Moreover, more than 7% of LC patients develop hepatocellular cancer in Japan and Taiwan, while the frequencies are less than 1.6% among other ethnic groups [6,7]. These inter-individual and inter-ethnic differences have been attributed to various factors such as viral genotypes,

Keywords: Genome-wide association study; Hepatitis C virus; Liver cirrhosis; Major histocompatibility complex.

Received 22 April 2012; received in revised form 15 December 2012; accepted 24 December 2012; available online 12 January 2013

* Corresponding author. Address: Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato, Tokyo 108-8639, Japan. Tel.: +81 3 5449 5376; fax: +81 3 5449 5123.

E-mail address: koichima@ims.u-tokyo.ac.jp (K. Matsuda).

Abbreviations: CHC, chronic hepatitis C; GWAS, genome-wide association study; HCV, hepatitis C virus; LC, liver cirrhosis; MHC, major histocompatibility complex; OR, odds ratio; PBC, primary biliary cirrhosis; SNPs, single nucleotide polymorphisms.



ELSEVIER

Research Article

Table 1. Characteristics of samples and methods used in this study.

Stage	Source	Platform	Number of samples	Female (%)	Age, yr (mean \pm SD)
GWAS					
Liver cirrhosis	BioBank Japan	Illumina Human Hap 610	682	313 (46.3)	67.1 \pm 9.7
Chronic hepatitis C ^a	Hiroshima University	Illumina Human Hap 610	1045	371 (35.5)	55.2 \pm 11.0
Replication					
Liver cirrhosis	Tokyo University	Invader assay	716	334 (46.8)	64.4 \pm 10.4
	Hiroshima University		220	98 (44.5)	64.7 \pm 8.98
Chronic hepatitis C ^a	BioBank Japan	Invader assay	1670	780 (46.8)	59.7 \pm 12.6
	Hiroshima University		2139	1061 (51.8)	58.8 \pm 9.20

^aNumber of samples that qualified. CHC patients with severe liver fibrosis (F3 or F4) or lower platelet counts (<160,000) were excluded.

alcohol consumption, age at infection, co-infection of HIV or HBV [8–10], insulin resistance, steatosis, and metabolic syndrome [11]. Previous gene expression analyses also identified various genes associated with liver fibrosis among patients with CHC [12–14]. In addition, miRNAs such as mir-21 and mir-122 were shown to be correlated with liver fibrosis [15,16].

Currently, the genome-wide association study is the most common method to identify genetic variations associated with disease risk [17–20]. In addition, the roles of genetic factors in HCV-related diseases have been elucidated. *IL28B* is associated with spontaneous clearance of HCV [21] as well as with the clinical response to the combination therapy of pegylated interferon and ribavirin [22,23]. Recently, our group has shown that SNP rs2596542 on *MICA* [24] and SNP rs1012068 on *DEPDC5* [25] are significantly associated with HCV-induced liver cancer. Although liver cirrhosis is the major risk factor of liver cancer, a fraction of CHC patients will develop HCC without accompanying LC. Therefore, the underlying genetic background would be different between HCV-induced LC and HCV-induced HCC. Previous studies identified the association of genetic variants in *HLA-DQ/DR/B* [26–28], *2-5AS* [29], *TLR3* [30], and *PNPLA3* [31] with the risk of liver fibrosis among patients with CHC. However, a comprehensive approach for HCV-induced LC has not been conducted so far. Here we performed GWAS of HCV-induced LC to identify predictive biomarkers for the risk of LC in patients with CHC.

Materials and methods

Ethics statement

All subjects provided written informed consent. This project was approved by the ethical committees at University of Tokyo, Hiroshima University, Sapporo Kosei General Hospital, Toranomon Hospital, and Center for Genomic Medicine, Institutes of Physical and Chemical Research (RIKEN).

Study population

The characteristics of each cohort are shown in Table 1. In this study, we conducted GWAS and replication analysis on a total of 1618 HCV-induced LC and 4854 CHC patients. All subjects had abnormal levels of serum alanine transaminase for more than 6 months and were positive for both HCV antibody and serum HCV RNA. Among 1618 LC and 4854 CHC samples, 342 LC patients (21.14%) and 2997 CHC patients (61.70%) underwent liver biopsy. The remaining 1276 LC and 1857 CHC patients were diagnosed by non-invasive methods including hepatic imaging (e.g., ultrasonography, computed tomography, arteriography or magnetic resonance imaging), biochemical data (serum bilirubin, serum albumin, platelet, or prothrombin time), and the presence/absence of clinical manifestations of portal hypertension (e.g., varices, encephalopathy or ascites). The patients with CHC

or LC were recruited for this study regardless of their treatment history. We excluded from the analysis the followings CHC patients: (1) advanced liver fibrosis (F3 or F4 by New Inuyama classification) [32], (2) platelet count under 160,000 for patients without liver fibrosis staging, and (3) HBV co-infection. Characteristics of each study cohort are shown in Table 1. In brief, DNA of HCV-induced LC and CHC patients was obtained from Biobank Japan (<http://biobankjp.org/>) [33], the Hiroshima Liver Study Group (<http://home.hiroshima-u.ac.jp/naika1/researchprofile/pdf/liverstudygroupe.pdf>), Toranomon Hospital, and the University of Tokyo. All subjects were of Japanese origin.

SNP genotyping

Genomic DNA was extracted from peripheral blood leukocytes using a standard method. In GWAS, we genotyped 682 LC and 1045 CHC samples using Illumina Human Hap 610-Quad bead Chip (Supplementary Fig. 1). Samples with low call rate (<0.98) were excluded from our analysis (six LC and two CHC samples). We then applied SNP quality control as follows: call rate ≥ 0.99 in LC and CHC samples, Hardy–Weinberg $p \geq 1 \times 10^{-6}$ in LC and CHC samples. Consequently, 461,992 SNPs on the autosomal chromosomes passed the quality control filters. SNPs with minor allele frequency of <0.01 in both LC and CHC samples were excluded from further analyses, considering statistical power in the replication analysis. Finally, we analyzed 431,618 SNPs in GWAS. Among the top ten SNPs showing $p < 1.0 \times 10^{-5}$, we selected nine SNPs for further analysis with LD threshold of $r^2 = 0.95$. In the replication stage, we genotyped 936 LC and 3809 CHC using multiplex PCR-based Invader assay (Third Wave Technologies).

Statistical analysis

The association of SNPs with the phenotype in the GWAS, replication stage, and combined analyses was tested by logistic regression analysis, upon adjusting for age at recruitment (continuous) and gender, by assuming additive model using PLINK [34]. In the GWAS, the genetic inflation factor λ was derived by applying logistic regressed p values for all the tested SNPs. The quantile–quantile plot was drawn using R program. The odds ratios were calculated using the non-susceptible allele as reference, unless stated otherwise. The combined analysis of GWAS and replication stage was verified by using the Mantel–Haenszel method. We set the significance threshold as follows; $p = 1 \times 10^{-5}$ in the GWAS stage (first stage) and $p = 6.25 \times 10^{-3}$ (=0.05/8) in the replication analysis. We considered $p < 5 \times 10^{-8}$ as threshold of GWAS significance in the combined analysis, which is the Bonferroni-corrected threshold for the number of independent SNPs genotyped in HapMap Phase II [35]. The heterogeneity across two stages was examined by using the Breslow–Day test [36]. We used Haploview software to analyze the association of haplotypes and LD values between SNPs. Quality control for SNPs was applied as follows: call rate ≥ 0.95 in LC and CHC samples, and Hardy–Weinberg $p \geq 1 \times 10^{-6}$ in CHC samples in replication stage. The statistical power was 19.51% in GWAS (the first stage) ($p = 1.00 \times 10^{-5}$), 97.98% in replication ($p = 0.05/8$), and 74.76% in the combined stage ($p = 5.00 \times 10^{-8}$) at minor allele frequency of 0.3 and OR of 1.3.

Imputation-based association analysis of HLA class I and class II alleles

We obtained an SNP or a combination of SNPs which could tag the HLA alleles in the Japanese population from a previous study [37]. Genotypes of tagging SNPs were imputed in the GWAS samples by using a Hidden Markov model programmed in MACH [38] and haplotype information from HapMap JPT samples




Fig. 1. Regional association plot at 6p21.3. (Upper panel) p Values of genotyped SNPs (circle) and imputed SNPs (cross) are plotted (as $-\log_{10} p$ value) against their physical position on chromosome 6 (NCBI Build 36). The p value for rs910049 at GWAS is represented by a purple diamond. Estimated recombination rates from HapMap JPT show the local LD structure. Inset; the color of the other SNPs indicates LD with rs135363 according to a scale from $r^2 = 0$ to $r^2 = 1$ based on pair-wise r^2 values from HapMap JPT. (Lower panel) Gene annotations from the University of California Santa Cruz genome browser.

and 1000 genome imputation samples [39]. We applied the same SNP quality criteria as in GWAS, to select SNPs for the analysis. We employed the logistic regression analysis upon age and gender adjustment to assess the associations between HCV-induced LC and HLA alleles.

Software

For general statistical analysis, we employed R statistical environment version 2.9.1 (cran.r-project.org) or plink-1.06 (pngu.mgh.harvard.edu/~purcell/plink/). The Haploview software version 4.2 [40] was used to calculate LD and to draw Manhattan plot. Primer3 -web v0.3.0 (<http://frodo.wi.mit.edu>) web tool was used to design primers. We employed LocusZoom (<http://csg.sph.umich.edu/locuszoom/>) for regional plots. We used SNP Functional Prediction web tool for functional annotation of SNPs (<http://snpinfo.niehs.nih.gov/snpfunc.htm>) [41]. We used "Gene Expression Analysis Based on Imputed Genotypes" (<http://www.sph.umich.edu/csg/liang/imputation>) [42] for eQTL analysis. We used MACTH [43] web tool for searching potential binding sites for transcription factors (<http://www.gene-regulation.com/index.htm>).

Results

Genome-wide association study for HCV-induced liver cirrhosis

We performed a two-stage GWAS using a total of 1618 cases and 4854 controls (Supplementary Fig. 1). In the first stage, a whole genome scan was performed on 682 Japanese patients with HCV-induced LC and 1045 Japanese patients with CHC, using Illumina Human Hap 610-Quad bead Chip. The genotyping results of 431,618 single nucleotide polymorphisms (SNPs) obtained after our standard quality control were used for further analysis.

CHC patients with severe liver fibrosis (F3 or F4 according to the New Inuyama classification [32]) or lower platelet counts ($<160,000$) were excluded from the control group. As progression from CHC to LC is strongly affected by age and gender, we performed logistic regression analyses including age and gender as covariates at all tested loci in our analyses. The genetic inflation factor lambda was 1.051, indicating that there is little or no evidence of population stratification (Supplementary Fig. 2A). Although no SNPs cleared the GWAS significance threshold ($p < 5 \times 10^{-8}$) at the first stage, we selected ten candidate SNPs showing suggestive association of $p < 1 \times 10^{-5}$ (Supplementary Fig. 2B and Supplementary Table 1). After excluding SNP rs6891116 due to almost absolute linkage with SNP rs10252674 ($r^2 = 0.99$), the remaining nine SNPs were further genotyped using an independent cohort, consisting of 936 LC and 3809 CHC cases, by multiplex PCR-based Invader assay as the second stage. We could successfully obtain genotype results for eight SNPs after the QC filter (call rate ≥ 0.95 in LC and CHC samples, Hardy-Weinberg of $p \geq 1 \times 10^{-6}$ in CHC samples). The logistic regression analysis adjusted by age and gender revealed that five SNPs on chromosome 6q21.3 indicated a significant association with progression from CHC to LC after the Bonferroni correction ($p < 0.05/8 = 6.25 \times 10^{-3}$, Supplementary Table 2). A meta-analysis of the two stages with a fixed-effects model revealed that all of the five SNPs significantly associated with progression from CHC to LC (p values of 9.15×10^{-11} – 1.28×10^{-8} with odds ratios (OR) of 1.30–1.46, Fig. 1 and Table 2). These five SNPs were located in the HLA class II region and were in strong linkage disequilibrium with each other ($D' > 0.75$,

Research Article

Table 2. Summary of GWAS and replication analyses.

SNP	Stage	Allele (1/2)	Gene	Liver cirrhosis				Chronic hepatitis C				OR (95% CI) ^b	p value ^c	p value _{het} ^d
				11	12	22	RAF ^a	11	12	22	RAF ^a			
rs910049	GWAS	a/g	<i>C6orf10</i>	24	217	435	0.196	25	224	794	0.131	1.73 (1.40-2.15)	5.39 × 10 ⁻⁷	
	Replication		(6p21.3)	38	259	631	0.180	66	952	2790	0.142	1.37 (1.20-1.58)	7.59 × 10 ⁻⁶	
	Combined ^e											1.46 (1.28-1.62)	9.15 × 10 ⁻¹¹	0.075
rs3817963	GWAS	a/g	<i>BTNL2</i>	92	343	241	0.390	101	437	505	0.306	1.53 (1.29-1.81)	9.50 × 10 ⁻⁷	
	Replication		(6p21.3)	130	395	395	0.356	409	1573	1816	0.315	1.22 (1.10-1.36)	2.66 × 10 ⁻⁴	
	Combined ^e											1.30 (1.18-1.42)	1.28 × 10 ⁻⁸	0.029
rs9405098	GWAS	a/g	No gene	75	293	308	0.328	70	365	608	0.242	1.54 (1.30-1.84)	1.10 × 10 ⁻⁶	
	Replication		(6p21.3)	100	361	462	0.304	249	1429	2129	0.253	1.30 (1.16-1.46)	5.64 × 10 ⁻⁶	
	Combined ^e											1.37 (1.23-1.50)	1.04 × 10 ⁻¹⁰	0.105
rs3135363	GWAS	c/t	No gene	35	258	383	0.757	89	447	507	0.700	1.58 (1.32-1.90)	7.89 × 10 ⁻⁷	
	Replication		(6p21.3)	73	322	540	0.750	389	1486	1929	0.702	1.30 (1.16-1.46)	7.94 × 10 ⁻⁶	
	Combined ^e											1.37 (1.24-1.51)	1.45 × 10 ⁻¹⁰	0.069
rs3129860	GWAS	a/g	No gene	58	294	324	0.303	57	348	638	0.221	1.55 (1.29-1.82)	6.45 × 10 ⁻⁶	
	Replication		(6p21.3)	88	339	507	0.276	208	1341	2246	0.231	1.28 (1.14-1.44)	2.53 × 10 ⁻⁵	
	Combined ^e											1.36 (1.22-1.49)	1.07 × 10 ⁻⁹	0.085

1618 (682 in GWAS and 936 in replication) liver cirrhosis and 4854 (1045 in GWAS and 3809 in replication) chronic hepatitis C samples were analyzed.

^aRAF, risk allele frequency.

^bOR, odds ratios; CI, confidence interval.

^cp Values obtained by logistic regression analysis adjusted for age and gender under additive model.

^dp Values of heterogeneities (Phet) across three stages were examined by using the Breslow–Day test.

^eCombined odds ratio and p values for independence test were calculated by Mendel-hauzen and Laird method in the meta-analysis.

Supplementary Fig. 3). To further evaluate the effect of each variation on the progression from CHC to LC, we performed multiple logistic regression analyses. As a result, rs910049 (p of 1.91×10^{-3} with OR of 1.25) and rs3135363 (p of 1.49×10^{-4} with OR of 1.23) remained significantly associated with the progression risk from CHC to LC, while the remaining three SNPs failed to show significant associations ($p > 0.05$) (Supplementary Table 3). Thus, two SNPs, rs910049 and rs3135363, seem to be independent risk factors for HCV-induced LC.

Since reduced platelet level is associated with a poor prognosis among CHC patients [44] we excluded patients with platelet level of less than 160,000 from CHC groups to increase the risk of type 2 error in this study. We also conducted the analysis using only CHC patients diagnosed with liver biopsy. As a result, both SNPs reached genome-wide significance ($p < 5 \times 10^{-8}$), although the associations were reduced due to the smaller sample size (Supplementary Table 4).

Subgroup analyses, stratified by IFN treatment status, amount of alcohol consumption, and gender, were also performed, since these factors were shown to be associated with the prognosis of CHC patients [45–47]. A total of 334 LC patients (35.83%) and 2325 CHC (82.4%) were treated with IFN therapy. Although the frequency of IFN treatment was different between CHC and LC groups, these variations associated with the LC risk regardless of IFN treatment as well as gender and alcohol consumption (Supplementary Fig. 4A–C). When we included these factors as covariates, the association of these variations with HCV-induced LC was sustained, with OR of 1.48 and 1.56, and SNP rs3135363

still reached genome-wide significance ($p = 3.95 \times 10^{-9}$) (Supplementary Table 5).

The association of previously reported variations with HCV-induced LC

Non-synonymous SNP rs738409 (I148M) in the *PNPLA3* gene was shown to be associated with progression of LC in the previous prospective study in Caucasians [31]. SNP rs738409 was also associated with the severity of non-alcoholic fatty liver disease in Japanese [48]. Therefore, we analyzed SNP rs738409 in our case-control cohort, but rs738409 did not significantly associate with HCV-induced LC ($p = 0.24$ and OR = 1.10), although the risk G allele was more frequent among LC than CHC (Supplementary Table 6). Our result is similar to what observed among Caucasians in the previous study, in which rs738409 increased liver cancer risk among alcoholic cirrhosis but did not among hepatitis C cirrhosis [49]. Since biological studies demonstrated that its risk allele (G) abolishes the triglyceride hydrolysis activity of *PNPLA3* [50] *PNPLA3* variation would have a strong impact on non-viral cirrhosis.

Recently, GWAS in the Caucasian population identified the association of SNPs rs4374383, rs16851720 and rs9380516 with the progression of liver fibrosis after HCV infection [51]. However, SNPs rs4374383 and rs16851720 did not exhibit significant association ($p = 0.654$ and 0.231 , respectively) in our sample set. Although SNP rs9380516 exhibited the association with p -value of 0.015, the risk allele showed an opposite result

Table 3. Results of three associated variations from candidate gene analyses.

Gene	Tagging SNP	Haplotype frequency		OR (95% CI) ^a	p value ^b	
		Liver cirrhosis	Chronic hepatitis C			
<i>DQA1*0601</i>	rs2736182(T) + rs2071293(A)	0.038	0.019	2.80	1.38-3.32	4.53 × 10 ⁻⁴
<i>DRB1*0405</i>	rs411326(C) + rs2395185(A) + rs4599680(A)	0.324	0.266	1.45	1.15-1.56	1.54 × 10 ⁻⁴

Association was tested by comparing haplotype distribution between 682 liver cirrhosis and 1045 chronic hepatitis C samples in GWAS.

^aOR, odds ratio; CI, confidence interval.

^bp Values were obtained by case-control analysis of GWAS stage (p for haplotype were obtained by score test, implemented in R) (*DQA1*0601* and *DRB1*0405*). The p values obtained by logistic regression analysis adjusted for age and gender under additive model.

(Supplementary Table 6). Taken together, these SNPs would not be associated with liver fibrosis in the Japanese population.

Genes related to extracellular matrix turnover or immune response (*KRT 19*, *COL1A1*, *STMN2*, *CXCL6*, *CCR2*, *TIMP1*, *IL8*, *IL1A*, *ITGA2*, *CLDN 4*, and *IL2*) were shown to be implicated in liver fibrosis of chronic hepatitis C [14]. To further characterize these loci, we conducted imputation analyses in the GWAS sample set (682 cases and 1045 controls), using data from HAPMAP phase II (JPT), and found 163 SNPs in 9 loci. However, none of these SNPs indicated significant association with p-value of less than 0.01 (Supplementary Table 7). Thus, variations of these genes did not associate with progression from chronic hepatitis C to liver cirrhosis.

Imputation-based fine mapping of HLA region

The most significantly associated SNP rs3135363 is located within an intergenic region between *BTNL2* and *HLA-DRA*, and rs910049 is located in intron 7 of *C6orf10* gene (Supplementary Figs. 5 and 6). To further characterize these loci, we conducted imputation-based association analysis for the GWAS samples (682 LC and 1045 CHC samples) using data from HAPMAP Phase II (JPT), and could obtain the results of nearly 6000 SNPs in a 4-Mb genomic region. The regional association plots revealed that all modestly-associated SNPs are confined within a 700-kb region containing 21 genes, namely *TNXB*, *ATF6B*, *FKBPL*, *PRRT1*, *PPT2*, *EGFL8*, *AGPAT1*, *RNF5*, *RNF5P1*, *AGER*, *PBX2*, *C6orf10*, *BTNL2*, *HLA-DRA*, *HLA-DRB5*, *HLA-DRB6*, *HLA-DRB1*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DQB1* and *HLA-DQB2* (Supplementary Fig. 5). Although 640 SNPs, including ten non-synonymous SNPs within the 4-Mb region, showed very modest associations ($p < 0.01$) with HCV-induced LC, none of these SNPs in this region revealed strong association with HCV-induced LC, after adjustment with the two SNPs, rs910049 and rs3135363 (Supplementary Fig. 7). Taken together, the associations observed in this region would reflect the association with rs910049 and rs3135363.

Previous reports indicated the association of *HLA-DRB1* and *HLA-DQ* alleles with HCV-induced chronic hepatitis in the Japanese population [26]. To investigate the association of HLA alleles with HCV-induced LC, we estimated the genotypes at the HLA region by applying the imputation results of HLA-tagging SNPs [37]. We could successfully determine 53 alleles of *HLA-A*, *B*, *C*, *DQA*, *DQB*, and *DRB* genes and find that *HLA-DQA1*0601* and *HLA-DRB1*0405* were strongly associated with HCV-induced LC (p values of 4.53×10^{-4} and 1.54×10^{-4} with ORs of 2.80 and 1.45) even after the Bonferroni correction ($p < 0.05/53 = 9.43 \times 10^{-4}$) (Table 3 and Supplementary Table 8A-E) [37].




Fig. 2. Cumulative effects of liver cirrhosis risk alleles. (A) Frequency distribution divided by risk allele numbers (rs910049, rs3135353, and *HLA-DQA0601*) among liver cirrhosis (light blue bars) and chronic hepatitis C (dark blue bars) patients. (B) Plot of the increase odds ratio (OR) for liver cirrhosis according to the number of risk alleles. The ORs are relative to the subjects with no risk alleles (rs910049, rs3135353, and *HLA-DQA0601*). Vertical bars correspond to 95% confidence intervals. Horizontal line marks the null value (OR = 1).

Cumulative effect of multiple loci within the HLA region

SNPs rs3135363 and rs910049, *HLA-DQA1*0601*, and *HLA-DRB1*0405* are located within a 300-kb segment in the HLA class II region and show moderate linkage disequilibrium (Supplementary Fig. 8). To further evaluate these genetic factors, we performed multiple logistic regression analyses and found that rs910049 (p of 9.40×10^{-3} with OR of 1.38), rs3135363 (p of 3.94×10^{-4} with OR = 1.41), and *HLA-DQA1*0601* (p of 7.79×10^{-3} with OR of 1.54) were significantly associated with HCV-induced LC (Supplementary Table 9), indicating these three variations were independent risk factors for progression of CHC to LC.

To investigate the pathophysiological roles of rs910049 and rs3135363 in disease progression, we searched the eQTL database (<http://www.sph.umich.edu/csg/liang/imputation>) and found that risk alleles of rs910049 (A) and rs3135363 (T) were associated with lower expression of *HLA-DQA* (LOD of ≥ 6.86 and 17.31, respectively) and *DRB1* (LOD of ≥ 12.01 and 18.96, respectively), and with higher expression of *HLA-DQB1* (LOD of ≥ 6.76 and 4.46, respectively) (Supplementary Table 10). Thus, rs910049 and rs3135363 are likely to affect the expression of HLA class II molecules and subsequently alter the risk of HCV-induced LC.

Finally, we examined the cumulative effects of rs910049, rs3135363, and *HLA-DQA1*0601*. Individuals with four or more risk alleles (8.8% of general population) have 2.83-fold higher risk of HCV-induced LC compared with those with no risk allele (15.0% of general population, Fig. 2).

Research Article

Discussion

We here demonstrated that multiple genetic variations in the MHC region were significantly associated with the risk of disease progression from CHC to LC, using a total of 1618 HCV-LC and 4854 CHC cases. Since a substantial proportion of patients with CHC show progression to LC in a certain time period, exclusion of CHC patients who have a high risk for LC from control subjects is essential to reduce the risk of false negative association. In this study, CHC patients with advanced fibrosis (F3 or F4 in stage) or with reduced platelet level (less than 160,000/ μ l) were excluded from the control samples, since these alterations are well-known risk factors for LC development [9,32]. Consequently, we were successfully able to identify the HCV-induced LC loci.

HLA genes are known to play critical roles in the regulation of our immune responses through controlling the antigen presentation to CD8 (class I) and CD4 (class II) T cells. Although previous studies indicated the association of HLA class I alleles such as *HLA-B57*, *HLA-A11*, and *HLA-C04* with persistent HCV infection [52,53], no SNPs in the HLA class I region exhibited strong association with HCV-induced LC. Here we identified three variations (rs910049, rs3135363, *HLA-DQA1*0601*) in the HLA class II region to be significantly associated with the progression risk from CHC to LC. Since two SNPs, rs910049 and rs3135363, had been indicated to affect expression levels of *HLA-DRB1* and *DQ*, our findings indicated the significant pathophysiological roles of HLA class II molecules in the development of HCV-induced liver fibrosis. Considering the function of *HLA-DQ* and *HLA-DR*, we suggest that the antigen presentation by HLA class II molecules is likely to play a critical role in the elimination of HCV-infected liver cells and subsequently prevent HCV-induced LC.

Direct acting antiviral drugs for HCV can cure up to 75% of patients infected with HCV genotype 1, and the lifetime risk of developing LC and HCC among HCV carriers was decreased during the two recent decades [54,13]. However, the amino acid sequence of the NS3 protease domain varies significantly between HCV genotypes and the antiviral efficacy differs in different HCV genotypes [55]. Moreover, protease inhibitors increased the incidence of adverse reactions such as anemia and skin rash [56]. Therefore, estimation of liver cirrhosis risk and prediction of treatment response would be essential to provide a personalized treatment and to achieve the optimal results. Due to the recent advances in pharmacogenetic studies, genetic factors associated with efficacy and adverse effects of anti-HCV treatment were identified. *IL-28B* is a powerful predictor of treatment outcome of pegylated interferon and ribavirin therapy [22], while a genetic variation in the *ITPA* gene was shown to be associated with ribavirin-induced anemia [57]. Since we conducted a retrospective study, and the majority of LC patients did not receive IFN treatment, we could not evaluate the treatment responses in our study design. However, SNPs identified in this study were associated with the LC risk independent of IFN treatment. Although the impact of each SNP was relatively weak compared with viral factors (HCV genotype, core and NS5A mutation [58]) and host factors (age, gender, obesity, and insulin resistance), we found that individuals with three or more risk alleles have a nearly three-fold higher risk of LC than those with no risk allele. Since lifetime risk of HCC development among HCV carriers is as high as about 27% for male and 8% for female [59], these three loci would have the strong effect on the clinical outcome of CHC patients. In general, the progression from chronic hepatitis C to liver cirrhosis usually takes more than 20–30 years. Therefore,

a large scale prospective cohort study with more than 10-year follow-up is essential to evaluate the role of these variations as a prognostic biomarker. We would like to perform prospective analysis in future studies. We hope that our findings would contribute to clarify the underlying molecular mechanism of HCV-induced liver cirrhosis.

Financial support

This work was conducted as a part of the BioBank Japan Project that was supported by the Ministry of Education, Culture, Sports, Science and Technology of the Japanese government.

Conflict of interest

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

Authors' contributions

Y. U., K. K., K. C., and K.M. conceived and designed the study; Y. U., H. O., N. K., Y. K., R. M., N. H., and M. K. performed genotyping; A. T., P. H. Y. L., C. T., and N. K. performed quality control at genome-wide phase; M. O., R. T., M. O., K. K., D. M., H. A., J. T., H. K., Y. N., K. M. and M. K. managed DNA samples; Y. U. analyzed and summarized the whole results; Y. U., Y. N., and K. M. wrote the manuscript; Y. N. obtained funding for the study.

Acknowledgments

We thank Ayako Matsui and Hiroe Tagaya (the University of Tokyo), and the technical staff of the Laboratory for Genotyping Development, Center for Genomic Medicine, RIKEN, for their technical support.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.jhep.2012.12.024>.

References

- [1] Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis* 2005;5:558–567.
- [2] Seeff LB. Natural history of chronic hepatitis C. *Hepatology* 2002;36:S35–S46.
- [3] Thomas DL, Seeff LB. Natural history of hepatitis C. *Clin Liver Dis* 2005;9:383–398, vi.
- [4] Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. *Hepatology* 2001;34:809–816.
- [5] Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. *Hepatology* 1997;9:155–205.
- [6] Tanaka H, Imai Y, Hiramatsu N, Ito Y, Imanaka K, Oshita M, et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. *Ann Intern Med* 2008;148:820–826.

- [7] Global burden of disease (GBD) for hepatitis C. *J Clin Pharmacol* 2004;44:20–29.
- [8] Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* 1997;349:825–832.
- [9] Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. *Ann Intern Med* 1999;131:174–181.
- [10] Zhang Q, Tanaka K, Sun P, Nakata M, Yamamoto R, Sakimura K, et al. Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients. *Neurobiol Dis* 2012;45:610–615.
- [11] Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, et al. A sustained virological response prevents development of insulin resistance in chronic hepatitis C patients. *Hepatology* 2012;56:549–556.
- [12] Bièche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. *Virology* 2005;332:130–144.
- [13] Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. *J Hepatol* 2012;57:1110–1125.
- [14] Asselah T, Bièche I, Laurendeau I, Paradis V, Vidaud D, Degot C, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. *Gastroenterology* 2005;129:2064–2075.
- [15] Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, Hoffer BA, Icardi MS, et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. *Lab Invest* 2010;90:1727–1736.
- [16] Morita K, Taketomi A, Shirabe K, Umeda K, Kayashima H, Ninomiya M, et al. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. *Liver Int* 2011;31:474–484.
- [17] Cui R, Okada Y, Jang SG, Ku JL, Park JG, Kamatani Y, et al. Common variant in 6q26-q27 is associated with distal colon cancer in an Asian population. *Gut* 2011;60:799–805.
- [18] Kumar V, Matsuo K, Takahashi A, Hosono N, Tsunoda T, Kamatani N, et al. Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility. *J Hum Genet* 2011;56:436–439.
- [19] Tanikawa C, Urabe Y, Matsuo K, Kubo M, Takahashi A, Ito H, et al. A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. *Nat Genet* 2012;44:430–434.
- [20] Urabe Y, Tanikawa C, Takahashi A, Okada Y, Morizono T, Tsunoda T, et al. A genome-wide association study of nephrolithiasis in the Japanese population identifies novel susceptible loci at 5q35.3, 7p14.3, and 13q14.1. *PLoS Genet* 2012;8:e1002541.
- [21] Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature* 2009;461:798–801.
- [22] Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 2009;41:1105–1109.
- [23] Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet* 2009;41:1100–1104.
- [24] Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. *Nat Genet* 2011;43:455–458.
- [25] Miki D, Ochi H, Hayes CN, Abe H, Yoshima T, Aikata H, et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. *Nat Genet* 2011;43:797–800.
- [26] Kuzushita N, Hayashi N, Moribe T, Katayama K, Kanto T, Nakatani S, et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. *Hepatology* 1998;27:240–244.
- [27] Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. *World J Gastroenterol* 2007;13:1770–1787.
- [28] Mosaad YM, Farag RE, Arafa MM, Eletreby S, El-Alfy HA, Eldeek BS, et al. Association of human leucocyte antigen Class I (HLA-A and HLA-B) with chronic hepatitis C virus infection in Egyptian patients. *Scand J Immunol* 2010;72:548–553.
- [29] Li CZ, Kato N, Chang JH, Muroyama R, Shao RX, Dharel N, et al. Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication. *Liver Int* 2009;29:1413–1421.
- [30] Mozer-Lisewska I, Sikora J, Kowala-Piaskowska A, Kaczmarek M, Dworacki G, Zeromski J. The incidence and significance of pattern-recognition receptors in chronic viral hepatitis types B and C in man. *Arch Immunol Ther Exp (Warsz)* 2010;58:295–302.
- [31] Trépo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. *Hepatology* 2011;54:60–69.
- [32] Romero-Gómez M, Gómez-González E, Madrazo A, Vera-Valencia M, Rodrigo L, Pérez-Alvarez R, et al. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. *Hepatology* 2008;47:810–816.
- [33] Nakamura Y. The BioBank Japan project. *Clin Adv Hematol Oncol* 2007;5:696–697.
- [34] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007;81:559–575.
- [35] Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al. A second generation human haplotype map of over 3.1 million SNPs. *Nature* 2007;449:851–861.
- [36] Breslow NE, Day NE. Statistical methods in cancer research. The design and analysis of cohort studies. *IARC Sci Publ* 1987;II:1–406.
- [37] de Bakker PI, McVean G, Sabeti PC, Miretti MM, Green T, Marchini J, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. *Nat Genet* 2006;38:1166–1172.
- [38] Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. *Science* 2007;316:1341–1345.
- [39] Consortium GP. A map of human genome variation from population-scale sequencing. *Nature* 2010;467:1061–1073.
- [40] Barrett J, Fry B, Maller J, Daly M. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005;21:263–265.
- [41] Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. *Nucleic Acids Res* 2009;37:W600–W605.
- [42] Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, Wong KC, et al. A genome-wide association study of global gene expression. *Nat Genet* 2007;39:1202–1207.
- [43] Kel AE, Gössling E, Reuter I, Cherepanov E, Kel-Margoulis OV, Wingender E. MATCH: a tool for searching transcription factor binding sites in DNA sequences. *Nucleic Acids Res* 2003;31:3576–3579.
- [44] Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003;38:518–526.
- [45] Cammà C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. *Hepatology* 2004;39:333–342.
- [46] Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. *Hepatology* 2002;36:547–556.
- [47] Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. *Gastroenterology* 1996;111:199–205.
- [48] Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. *PLoS One* 2012;7:e38322.
- [49] Nischalke HD, Berger C, Luda C, Berg T, Müller T, Grünhage F, et al. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. *PLoS One* 2011;6:e27087.
- [50] He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. *J Biol Chem* 2010;285:6706.
- [51] Patin E, Kutalik Z, Guernon J, Bibert S, Nalpas B, Jouanguy E, et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. *Gastroenterology* 2012;143:124–152, e1–12.
- [52] Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyrol LL, et al. Spontaneous control of HCV is associated with expression of HLA-B*57 and preservation of targeted epitopes. *Gastroenterology* 2011;140:e681.
- [53] Fanning LJ, Kenny-Walsh E, Shanahan F. Persistence of hepatitis C virus in a white population: associations with human leukocyte antigen class I. *Hum Immunol* 2004;65:745–751.

Research Article

- [54] Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). *Hepatology* 2011;53:1090–1099.
- [55] Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. *Liver Int* 2012;32:88–102.
- [56] Ozeki I, Akaike J, Karino Y, Arakawa T, Kuwata Y, Ohmura T, et al. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. *J Gastroenterol* 2011;46:929–937.
- [57] Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy – a genome-wide study of Japanese HCV virus patients. *Gastroenterology* 2010;139:1190–1197.
- [58] Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 1996;334:77–82.
- [59] Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. *J Clin Oncol* 2011;29:3643–3650.

Identification of a Functional Variant in the *MICA* Promoter Which Regulates *MICA* Expression and Increases HCV-Related Hepatocellular Carcinoma Risk

Paulisally Hau Yi Lo¹, Yuji Urabe^{1,2}, Vinod Kumar¹, Chizu Tanikawa¹, Kazuhiko Koike³, Naoya Kato⁴, Daiki Miki^{2,5}, Kazuaki Chayama^{2,5}, Michiaki Kubo⁵, Yusuke Nakamura^{1,6}, Koichi Matsuda^{1*}

1 Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan, **2** Departments of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan, **3** Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, **4** Unit of Disease Control Genome Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan, **5** Center for Genomic Medicine, The Institute of Physical and Chemical Research (RIKEN), Kanagawa, Japan, **6** Departments of Medicine and Surgery, and Center for Personalized Therapeutics, The University of Chicago, Chicago, Illinois, United States of America

Abstract

Hepatitis C virus (HCV) infection is the major cause of hepatocellular carcinoma (HCC) in Japan. We previously identified the association of SNP rs2596542 in the 5' flanking region of the *MHC class I polypeptide-related sequence A (MICA)* gene with the risk of HCV-induced HCC. In the current study, we performed detailed functional analysis of 12 candidate SNPs in the promoter region and found that a SNP rs2596538 located at 2.8 kb upstream of the *MICA* gene affected the binding of a nuclear protein(s) to the genomic segment including this SNP. By electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assay, we identified that transcription factor Specificity Protein 1 (SP1) can bind to the protective G allele, but not to the risk A allele. In addition, reporter construct containing the G allele was found to exhibit higher transcriptional activity than that containing the A allele. Moreover, SNP rs2596538 showed stronger association with HCV-induced HCC ($P = 1.82 \times 10^{-5}$ and $OR = 1.34$) than the previously identified SNP rs2596542. We also found significantly higher serum level of soluble MICA (sMICA) in HCV-induced HCC patients carrying the G allele than those carrying the A allele ($P = 0.00616$). In summary, we have identified a functional SNP that is associated with the expression of *MICA* and the risk for HCV-induced HCC.

Citation: Lo PHY, Urabe Y, Kumar V, Tanikawa C, Koike K, et al. (2013) Identification of a Functional Variant in the *MICA* Promoter Which Regulates *MICA* Expression and Increases HCV-Related Hepatocellular Carcinoma Risk. PLoS ONE 8(4): e61279. doi:10.1371/journal.pone.0061279

Editor: Erica Villa, University of Modena & Reggio Emilia, Italy

Received: September 24, 2012; **Accepted:** March 11, 2013; **Published:** April 11, 2013

Copyright: © 2013 Lo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of the Japanese government, the Ministry of Health, Labour, and Welfare of the Japanese government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: koichima@ims.u-tokyo.ac.jp

Introduction

Hepatocellular carcinoma (HCC) is one of the common cancers in the world. It is well-known to be associated with the chronic infection of Hepatitis B (HBV) and Hepatitis C (HCV) viruses. In Japan, nearly 70% of HCC patients are infected with HCV [1]. The annual rate of developing HCC among patients with HCV-related liver cirrhosis in Japan is estimated to be about 4–8 percent [2]. Recent analyses have identified various genetic factors that are related with viral induced liver diseases [3–5]. In our previous two-stage genome-wide association study (GWAS) using a total number of 1,394 cases and 5,486 controls, a SNP rs2596542 located on chromosome 6p21.33 was shown to be significantly associated with HCV-induced HCC ($P = 4.21 \times 10^{-13}$ and $OR = 1.39$) [6]. This SNP is located within the class I major histocompatibility complex (MHC) region and is at about 4.8 kb upstream of *MHC class I polypeptide-related sequence A (MICA)* gene. We also identified that the risk A allele of SNP rs2596542 was strongly associated with the low expression of soluble MICA (sMICA) in the serum of HCV-related HCC patients [6].

MICA is a membrane protein which is up-regulated in various tumor cells and also induced in response to various cellular stresses such as infection, hypoxia, and heat shock [7]. It is an important component of the innate immune response, as *MICA* can bind to the NKG2D receptor and subsequently activate natural killer (NK) cells, CD8+ cells, and $\gamma\delta$ T cells [8,9]. Moreover, membrane *MICA* can be shed by metalloproteinases, including MMP9, ADAM10, and ADAM17, and secreted into serum as a soluble form [10,11]. Since these metalloproteinases are often activated in HCC, the expressions of both membrane-bound *MICA* and sMICA are increased [12,13]. SNP rs2596542 was found to be associated with the progression from chronic hepatitis C (CHC) to HCC and also with serum sMICA level. Hence, both rs2596542 and sMICA would be possible prognostic biomarkers for CHC patients. However, their underlying molecular mechanisms were not fully elucidated so far.

We hypothesize that *MICA* variations could affect sMICA level by either one or both of the following two possible mechanisms: (1) the genetic variation(s) in the coding region affecting the protein stability and (2) the transcriptional regulation. Previously, variable